The Hypoxia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoxia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoxia and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Hypoxia by eight companies/universities/institutes. The top development phase for Hypoxia is preclinical with six drugs in that stage. The Hypoxia pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypoxia pipeline products market are: Bioxytran, Aodh Lifesciences and Stream Biomedical.
The key targets in the Hypoxia pipeline products market include Nitric Oxide Synthase Inducible, Nitric Oxide Synthase Brain, and Hemoglobin.
The key mechanisms of action in the Hypoxia pipeline product include Nitric Oxide Synthase Inducible Inhibitor with one drug in Phase II. The Hypoxia pipeline products include four routes of administration with the top ROA being Intravenous and five key molecule types in the Hypoxia pipeline products market including Small Molecule, and Polymer.
Hypoxia overview
Hypoxia is a condition in which oxygen is not available in sufficient amounts at the tissue level to maintain adequate homeostasis; this can result from inadequate oxygen delivery to the tissues either due to low blood supply or low oxygen content in the blood (hypoxemia). Hypoxia can vary in intensity from mild to severe and can present in acute or chronic form.
For a complete picture of Hypoxia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
